Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 16 years, with Q2 2025 value amounting to -$3.5 million.

  • Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses fell 15995.54% to -$3.5 million in Q2 2025 from the same period last year, while for May 2025 it was -$5.9 million, marking a year-over-year decrease of 45807.62%. This contributed to the annual value of -$5.9 million for FY2025, which is 45807.62% down from last year.
  • According to the latest figures from Q2 2025, Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses is -$3.5 million, which was down 15995.54% from -$886000.0 recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses' 5-year high stood at $13.2 million during Q1 2023, with a 5-year trough of -$13.1 million in Q2 2023.
  • Moreover, its 5-year median value for Change in Accured Expenses was -$1.2 million (2021), whereas its average is -$702888.9.
  • Per our database at Business Quant, Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses soared by 38075.16% in 2022 and then crashed by 241502.89% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Change in Accured Expenses (Quarter) stood at -$2.0 million in 2021, then increased by 9.6% to -$1.8 million in 2022, then soared by 86.11% to -$246000.0 in 2023, then tumbled by 412.6% to -$1.3 million in 2024, then plummeted by 177.48% to -$3.5 million in 2025.
  • Its Change in Accured Expenses was -$3.5 million in Q2 2025, compared to -$886000.0 in Q1 2025 and -$1.3 million in Q4 2024.